Eric Lefkofsky: Working to Modernize Cancer Treatment

One of Chicago area’s most entreprenurial tech-sci figures, Eric Lefkofsky has donated millions of dollars into cancer research trials and studies, as he has been running the race of the medical field’s most important marathon for decades: curing cancer.

Leaving his CEO role at Groupon, Lefkofsky is busy heading new health-tech company, “Tempus,” which is attempting to build an infrastructure to modernize cancer treatment around the world. To date, he is titled as the company’s President.

Lefkofsky’s exact level of involvement with Tempus is something he avoids explaining, at least to some media venues who have tried to gain a clear understanding of why he left Groupon, as he was founder. What is it about Tempus that compelled him to invest his time and energy into a new undertaking.

LinkedIn reading states that Tempus employs 29 employees. Hunter Lane is named as Director. Anil Saldanha is Vice President of Engineering. Tempus’ primary mission [https://www.tempus.com] states it is interested in effectively aiding healthcare professionals in personalized, data-driven treatment decisions. This may make a beginning by analyzing patient genetic codes, using state-of-art “genomic sequencing,” not exactly a clear job description to the lay man. This is allegedly focused on malignant tumors, and involves a slightly new term, “algorithms”. This includes breast, lung, and pancreatic cancers, and expects to delve into other types in the future.

Lefkofsky’s wife Liz joins him in consistently donating to cancer research causes through their Lefkofsky Family Foundation, including money donated to New York’s Weill Cornell Medicine for breast cancer research in the amount of $250k.

Lefkofsky writes in his blog about how artificial intelligence is moving research forward, and of primary importance must be in healthcare. He explains how there is so many unused intel within data of molecular studies and documentation. Mentioned earlier,
he continually reiterates the significance of a personalized method of treatment; that there is a unique molecular map of each human being alive. Finding out the treasure to this map, so to speak, will give us the exact targets to attack in the fight against cancer by one thousand fold! This dictates personalized drugs, therapies, regimen and sequence.

“Accelerated Disruption: Understanding the True Speed of Innovation” (Easton Studio Press, 2007) is authored by the entrepreneur, shedding light on how so many businesses must understand and gain control of latest technological advances. Those that do will accomplish phenomenal feats; those who don’t or can’t will dissolve.

The 43-year-old seems to be just getting started in his latest undertaking of Tempus work, and will probably remain focused on healthcare research of causes and cures, if there truly is a cure, of cancer. This might be assured by his proven track record devoted to spending his lifetime, energy and unstoppable enthusiasm in uncovering, delving into, and figuring out the puzzles that seem to make up the many versions of cancer that plague so many people today.

What Eric Lefkofsky may offer the world, perhaps most importantly, is the gift of hope. Over one million people will be diagnosed with cancer in 2017, worldwide. Today, 4 out of 10 cancer patients will survive the symptoms of their disease. Annually to date, medical costs alone totals $37 billion. But perhaps the most motivating statistic is this: anyone, living anywhere, no matter how optimum their health is at risk.